| Literature DB >> 34240627 |
Emma Gulley1, Joe Verghese1,2, Helena M Blumen1,2, Emmeline Ayers1, Cuiling Wang3, Russell K Portenoy1,4,5,6, Jessica L Zwerling1, Erica Weiss1, Helena Knotkova4,5.
Abstract
New therapies for symptoms in Alzheimer's disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT04404153 (Clinicaltrials.gov).Entities:
Keywords: Alzheimer’s disease; at-home tDCS; clinical trial protocol; dementia; noninvasive neurostimulation; transcranial direct current stimulation (tDCS)
Mesh：
Year: 2021 PMID： 34240627 PMCID： PMC8438943 DOI： 10.2217/nmt-2020-0061
Source DB: PubMed Journal: Neurodegener Dis Manag ISSN： 1758-2024